Elanco Q2 rev +5% to $1.24B, raises FY2025 outlook; net leverage target improved

Elanco Animal Health Inc

2025-Q2 EPS reported $0.16 revenue$2,434,000,000

Q2 revenue $1,241M (+5% reported, +8% organic CC); adjusted EPS $0.26 vs $0.30 prior year.
FY2025 revenue guidance raised to $4,570-4,620M; adjusted EPS raised to $0.85-0.91.
Full-year innovation revenue target increased by $60M to $720-800M; Credelio Quattro and Experior drive growth.
Net leverage ratio improved to 4.0x at Q2 end; year-end target tightened to 3.8x-4.1x.
Robert VanHimbergen appointed EVP and CFO effective July 7, 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.